Tirzepatide 10 mg: Next-Generation Dual GIP/GLP-1 Agonist

What is Tirzepatide 10 mg (Mounjaro)?

Tirzepatide 10 mg is an advanced, next-generation peptide belonging to the class of dual receptor agonists for GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). Known in clinical settings under the brand name Mounjaro, it represents a direct evolution of mono-agonist drugs such as semaglutide (Ozempic/Wegovy).

The 10 mg dose is specifically recommended for athletes and individuals who have already completed the initial titration phase (2.5 mg and 5 mg) and need a higher concentration to consolidate weight loss, maximize their caloric deficit without feeling hungry, and preserve lean muscle mass during the most rigorous training periods.

Mechanism of Action: The GIP + GLP-1 Synergy

Unlike traditional adrenergic thermogenic compounds (such as Clenbuterol or Ephedrine), Tirzepatide 10 mg does not stimulate the central nervous system and does not place excessive strain on the cardiovascular system. Its mechanism of action involves the combined activation of two incretin hormones:

• GLP-1 Action: Slows gastric emptying, signals immediate satiety to the hypothalamic centers, and stabilizes postprandial insulin secretion.

• GIP Action: Improves insulin sensitivity in adipose tissue, promotes the oxidation of free fatty acids, and reduces the accumulation of ectopic triglycerides.

This synergistic effect ensures a significantly greater reduction in hunger and optimal glycemic control compared to GLP-1 agonists alone.

Benefits of Tirzepatide 10 mg in Bodybuilding and Body Composition Transformation

• Targeted appetite suppression: Eliminates bouts of compulsive hunger and carbohydrate cravings, making even very low-calorie diets (PSMF or contest prep) sustainable.

• Improved nutrient partitioning: Directs ingested carbohydrates toward the replenishment of muscle glycogen rather than toward fat stores.

• No side effects from stimulants: No tachycardia, tremors, anxiety, or insomnia—symptoms typical of traditional thermogenics.

• Preservation of lean body mass: By optimizing metabolic efficiency and reducing systemic inflammation, it promotes the selective loss of visceral and subcutaneous fat.

Protocols for Use and Administration

The molecule is formulated as a sterile, 10-mg lyophilized powder and must be reconstituted with bacteriostatic water.

• Route of administration: Subcutaneous injection (abdomen, thigh, or deltoid muscle) using an insulin syringe.

• Frequency: 1 dose every 7 days (plasma half-life of approximately 5 days).

• Dosage Guidelines: The 10 mg vial is ideal for those already on a maintenance or advanced regimen (e.g., a single weekly dose of 10 mg, or divided into two 5 mg doses per vial).

• Note for beginners: Never start directly with 10 mg; gradual titration beginning at 2.5 mg is essential to prevent gastrointestinal upset.

Storage and Maintenance

• Unreconstituted product: Store in a cool, dry place, away from direct light and heat sources (or in the refrigerator at 2–8°C to ensure long-term stability).

• Reconstituted product: Must be stored in the refrigerator at a temperature between 2°C and 8°C. Use within 30–45 days after mixing. Do not freeze.

Quality Assurance: FIG Farma & Driada Medical

All batches of Tirzepatide 10 mg distributed by FIG Farma come directly from Driada Medical’s certified manufacturing facility.

Each package includes:

• A unique verification code to verify authenticity on the manufacturer's official website.

• HPLC and mass spectrometry analysis reports guaranteeing a purity of over 99%.

• Secure, traceable shipping that complies with privacy standards.